Literature DB >> 20829610

Epidemiology of Cushing's syndrome.

Charlotte Steffensen1, Ann Mosegaard Bak, Kristine Zøylner Rubeck, Jens Otto Lunde Jørgensen.   

Abstract

Overt Cushing's syndrome is a rare disorder with an annual incidence of 2-3/million of which benign adrenal adenomas account for 0.6/million. The female:male ratio is 3:1. Preliminary data indicate a high proportion of subclinical Cushing's syndrome in certain risk populations such as patients with type 2 diabetes or osteoporosis. The clinical implications of these observations are presently unclear. Surgery remains first line treatment for overt disease and initial cure or remission is obtained in 65-85% of patients with Cushing's disease. Late recurrences, however, occur in up to 20% and the risk does not seem to plateau even after 20 years of follow-up. A 2- to 3-fold increase in mortality is observed in most studies, and this excess mortality seems confined to patients in whom initial cure was not obtained. Cushing's syndrome continues to pose diagnostic and therapeutic challenges and life-long follow-up is mandatory.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2010        PMID: 20829610     DOI: 10.1159/000314297

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  51 in total

1.  Diagnostic performance of late-night salivary cortisol measured by automated electrochemiluminescence immunoassay in obese and overweight patients referred to exclude Cushing's syndrome.

Authors:  Zhanna E Belaya; Alexander V Iljin; Galina A Melnichenko; Liudmila Y Rozhinskaya; Natalia V Dragunova; Larisa K Dzeranova; Svetlana A Butrova; Ekaterina A Troshina; Ivan I Dedov
Journal:  Endocrine       Date:  2012-03-25       Impact factor: 3.633

2.  Surgical outcomes in patients with Cushing's disease: the Cleveland clinic experience.

Authors:  Philip C Johnston; Laurence Kennedy; Amir H Hamrahian; Zahrae Sandouk; James Bena; Betul Hatipoglu; Robert J Weil
Journal:  Pituitary       Date:  2017-08       Impact factor: 4.107

Review 3.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

Review 4.  Ectopic ACTH-secreting pituitary adenomas within the sphenoid sinus.

Authors:  Philip C Johnston; Laurence Kennedy; Robert J Weil; Amir H Hamrahian
Journal:  Endocrine       Date:  2014-06-14       Impact factor: 3.633

Review 5.  Managing Cushing's disease: the state of the art.

Authors:  Annamaria Colao; Marco Boscaro; Diego Ferone; Felipe F Casanueva
Journal:  Endocrine       Date:  2014-01-11       Impact factor: 3.633

6.  ACTH-secreting pituitary adenomas: size does not correlate with hormonal activity.

Authors:  Nestoras Mathioudakis; Courtney Pendleton; Alfredo Quinones-Hinojosa; Gary S Wand; Roberto Salvatori
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

7.  Safety of transsphenoidal microsurgical approach in patients with an ACTH-secreting pituitary adenoma.

Authors:  Carmine Antonio Donofrio; Marco Losa; Marco Gemma; Lodoviga Giudice; Lina Raffaella Barzaghi; Pietro Mortini
Journal:  Endocrine       Date:  2016-12-22       Impact factor: 3.633

8.  The treatment with pasireotide in Cushing's disease: effects of long-term treatment on tumor mass in the experience of a single center.

Authors:  Chiara Simeoli; Renata Simona Auriemma; Fabio Tortora; Monica De Leo; Davide Iacuaniello; Alessia Cozzolino; Maria Cristina De Martino; Claudia Pivonello; Ciro Gabriele Mainolfi; Riccardo Rossi; Sossio Cirillo; Annamaria Colao; Rosario Pivonello
Journal:  Endocrine       Date:  2015-03-06       Impact factor: 3.633

9.  Incidence of Cushing's syndrome and Cushing's disease in commercially-insured patients <65 years old in the United States.

Authors:  Michael S Broder; Maureen P Neary; Eunice Chang; Dasha Cherepanov; William H Ludlam
Journal:  Pituitary       Date:  2015-06       Impact factor: 4.107

10.  Mapping CushingQOL scores to EQ-5D utility values using data from the European Registry on Cushing's syndrome (ERCUSYN).

Authors:  X Badia; M Roset; E Valassi; H Franz; A Forsythe; S M Webb
Journal:  Qual Life Res       Date:  2013-03-29       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.